Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

L.A. McKeown

July 11, 2023

News Daily News

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

L.A. McKeown

April 15, 2022

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

The finding, from a study with a mean follow-up of 2-and-a-half years, bolsters support for trials and device use to continue.

News Daily News

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

L.A. McKeown

December 18, 2020

News Daily News

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

L.A. McKeown

August 12, 2020

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

News Conference News ISC 2019

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

Todd Neale

February 12, 2019

News Daily News

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

L.A. McKeown

January 03, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Industry News

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

August 14, 2015

Advertisement

Popliteal Interventions Linked to Higher Long-term Amputation Risk Than SFA

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

SWEDEPAD: No Mortality Signal With Paclitaxel in PAD

CV Prevention Meds Underused in Hispanic, Latinx PAD Patients

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke

AHA Scientific Statement: Get PAD Patients Moving to Improve Symptoms and QoL

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Proteon Therapeutics Announces Top-Line Results From Phase 1 Study of Investigational Drug Vonapanitase in Patients With Symptomatic Peripheral Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content